removal of BET from plasma protein through DEAE resin


Removing bovine endogenous retrovirus (BERV) or Bovine exogenous retrovirus (BERV) from plasma protein through DEAE (Diethylaminoethyl) resin anion-exchange chromatography is a common method. DEAE resin is a type of anion-exchange resin that can be used for the purification of plasma proteins. Here are the general steps for removing BET from plasma protein through DEAE resin anion-exchange chromatography:

1.    Prepare the sample: The plasma protein sample should be clarified and filtered to remove any debris or contaminants before being loaded onto the column.

2.    Equilibrate the column: The column should be equilibrated with a buffer that is compatible with the DEAE resin. A common buffer used is a low salt buffer such as Tris-HCl, pH8.0

3.    Load the sample: The plasma protein sample is then loaded onto the column, and the BET proteins are retained by the DEAE resin while the other proteins pass through.

4.    Wash the column: The column is washed with a buffer to remove any non-specifically bound proteins, and to further purify the plasma protein sample. The buffer used for washing should have a lower salt concentration than the equilibration buffer.

5.    Elute the protein: The plasma protein is then eluted from the column using a buffer with a higher salt concentration, this will release the plasma proteins from the DEAE resin, while the BET proteins remain bound.

6.    Concentrate and buffer exchange the eluted protein: The eluted protein is then concentrated and buffer-exchanged to remove the salt, if necessary.

7.    Quality control: The final protein sample should be analyzed for quality control, such as protein concentration, purity, and activity, to ensure that BET proteins have been effectively removed.

It's important to note that different anion-exchange resins may have different binding properties and different plasma protein samples may have different BET protein concentrations, so the specific conditions for DEAE resin anion-exchange chromatography will need to be optimized. Additionally, it may be necessary to use additional chromatography techniques, such as size-exclusion or affinity chromatography, to achieve optimal BET removal from the plasma protein.

Comments

Post a Comment

Popular posts from this blog

MOA OF AMINOGLYCOSIDE ANTIBIOTICS

Image
MOA                  of   Aminoglycoside             Antibiotics Aminoglycosides exert their bactericidal effect by inhibiting protein synthesis in bacteria and compromising the structure of the bacterial cell wall . Aminoglycoside Antibiotics Aminoglycoside antibiotics are used to treat serious infections caused by gram-negative bacteria . Some commonly used aminoglycosides include: amikacin (Amikin®); apramycin; capreomycin; gentamicin (Garamycin®); kanamycin (Kantrex®); neomycin (Mycifradin®); netilmicin (Netromycin®); paromomycin (Humatin®); streptomycin; tobramycin (TOBI Solution®, TobraDex®, Nebcin®) Mode of Action Although aminoglycosides stop bacteria from making proteins, it is uncertain whether this is the action that results in bacterial cell death.     Disruption of Protein Synthesis A minoglyco s i d e s b i n d to the b a c t er i al 3 0 S r i b o s o mal s ubunit. R i b o s om e s are the p ro t e i n
Read more

article review on adalimumab production

Adalimumab is a recombinant human monoclonal antibody that is used to treat a variety of inflammatory diseases, such as rheumatoid arthritis, psoriasis, and Crohn's disease. It is produced using recombinant DNA technology in Chinese hamster ovary (CHO) cells. A research article "Development of a high-titer, high-density fed-batch process for the production of adalimumab in CHO cells" by Chen et al. (2018) aimed to improve the production of adalimumab by developing a high-titer and high-density fed-batch process. The study used a CHO cell line that had been modified to express the adalimumab gene. The cells were grown in a culture medium containing glucose, amino acids, and a proprietary feed supplement, and the culture conditions were optimized to achieve high yields of the protein. The results of the study showed that a high yield of adalimumab (over 2g/L) was achieved using the fed-batch cultivation system. The study also found that the specific productivity of th
Read more